Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for neutropenia in GSD1b and G6PC3 deficiency
2018-004191-35Phase 4Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin in glycogen storage disease type 1b and severe congenital neutropenia (SCN), sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: Safety. Started Mar 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
glycogen storage disease type 1bsevere congenital neutropenia (SCN)
Beyond the preview
Go deeper on 2018-004191-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004191-35.